NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 993.5 DKK | -1.10% |
|
-3.36% | +42.31% |
| 06:04am | US President Calls Out Eli Lilly, Novo Nordisk Over High Drug Prices | MT |
| 05:57am | US President Calls Out Eli Lilly, Novo Nordisk Over High Drug Prices | MT |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.31% | 634B | |
| +55.55% | 816B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.02% | 238B | |
| +1.64% | 222B | |
| +13.66% | 218B | |
| +7.87% | 167B | |
| -3.33% | 158B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- European Equities Close Higher in Thursday Trading; Euro Area Inflation Falls More Than Expected
